HLS Therapeutics (TSE:HLS) Hits New 1-Year Low – Time to Sell?

HLS Therapeutics Inc. (TSE:HLS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$4.20 and last traded at C$4.24, with a volume of 21422 shares changing hands. The stock had previously closed at C$4.36.

HLS Therapeutics Stock Down 2.5%

The stock has a market cap of C$132.92 million, a PE ratio of -13.28 and a beta of -0.02. The business has a 50 day moving average of C$4.55 and a 200-day moving average of C$4.60. The company has a current ratio of 1.00, a quick ratio of 1.01 and a debt-to-equity ratio of 75.00.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings data on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. The firm had revenue of C$17.88 million during the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. Equities research analysts predict that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.